Search research articles
Contact Us
Filters
Showing results (71-80 of 97) with videos related to
Page
of 10
Sort By:
Biopharmaceutics & Drug Disposition
|
June 19, 2007
Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers
Arthur Bergman, David Ebel, Fang Liu, et al.
Clinical Pharmacokinetics
|
April 28, 2020
Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
Daryl J Fediuk, Gianluca Nucci, Vikas Kumar Dawra, et al.
Therapeutic Innovation & Regulatory Science
|
September 21, 2018
Novel Gastroretentive Controlled Release Formulations for Once-Daily Administration: Assessment of Clinical Feasibility and Formulation Concept for Raltegravir
Rajesh Krishna, Matthew L Rizk, Patrick J Larson, et al.
Journal of Clinical Pharmacology
|
April 4, 2021
Meta-Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure
Jean-Claude Marshall, Yali Liang, Vaishali Sahasrabudhe, et al.
Clinical Pharmacology in Drug Development
|
November 15, 2018
Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed-Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin
Vaishali Sahasrabudhe, Daryl J Fediuk, Kyle Matschke, et al.
Journal of Clinical Pharmacology
|
April 27, 2010
Effect of diltiazem, a moderate CYP3A inhibitor, on the pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein inhibitor, in healthy subjects
Amit Garg, Andrea Maes, Christy Corr, et al.
Clinical Pharmacology in Drug Development
|
May 23, 2018
Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects
Vikas Kumar Dawra, David L Cutler, Susan Zhou, et al.
Clinical Pharmacology and Therapeutics
|
July 11, 2024
New Horizons of Model Informed Drug Development in Rare Diseases Drug Development
Amitava Mitra, Nessy Tania, Mariam A Ahmed, et al.
Journal of Clinical Pharmacology
|
June 19, 2008
Lack of erectogenic activity of a novel selective melanocortin-4 receptor agonist in a clinical experimental model
Rajesh Krishna, Peggy Wong, Catherine Stevens, et al.
Clinical Pharmacology and Therapeutics
|
June 14, 2023
Model-Informed Approaches and Innovative Clinical Trial Design for Adeno-Associated Viral Vector-Based Gene Therapy Product Development: A White Paper
Amitava Mitra, Mariam A Ahmed, Rajesh Krishna, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 97) with videos related to
Sort By:
Page
of 10
Biopharmaceutics & Drug Disposition
|
June 19, 2007
Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers
Arthur Bergman, David Ebel, Fang Liu, et al.
Clinical Pharmacokinetics
|
April 28, 2020
Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
Daryl J Fediuk, Gianluca Nucci, Vikas Kumar Dawra, et al.
Therapeutic Innovation & Regulatory Science
|
September 21, 2018
Novel Gastroretentive Controlled Release Formulations for Once-Daily Administration: Assessment of Clinical Feasibility and Formulation Concept for Raltegravir
Rajesh Krishna, Matthew L Rizk, Patrick J Larson, et al.
Journal of Clinical Pharmacology
|
April 4, 2021
Meta-Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure
Jean-Claude Marshall, Yali Liang, Vaishali Sahasrabudhe, et al.
Clinical Pharmacology in Drug Development
|
November 15, 2018
Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed-Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin
Vaishali Sahasrabudhe, Daryl J Fediuk, Kyle Matschke, et al.
Journal of Clinical Pharmacology
|
April 27, 2010
Effect of diltiazem, a moderate CYP3A inhibitor, on the pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein inhibitor, in healthy subjects
Amit Garg, Andrea Maes, Christy Corr, et al.
Clinical Pharmacology in Drug Development
|
May 23, 2018
Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects
Vikas Kumar Dawra, David L Cutler, Susan Zhou, et al.
Clinical Pharmacology and Therapeutics
|
July 11, 2024
New Horizons of Model Informed Drug Development in Rare Diseases Drug Development
Amitava Mitra, Nessy Tania, Mariam A Ahmed, et al.
Journal of Clinical Pharmacology
|
June 19, 2008
Lack of erectogenic activity of a novel selective melanocortin-4 receptor agonist in a clinical experimental model
Rajesh Krishna, Peggy Wong, Catherine Stevens, et al.
Clinical Pharmacology and Therapeutics
|
June 14, 2023
Model-Informed Approaches and Innovative Clinical Trial Design for Adeno-Associated Viral Vector-Based Gene Therapy Product Development: A White Paper
Amitava Mitra, Mariam A Ahmed, Rajesh Krishna, et al.
Page
of 10